Hims & Hers Health (NYSE:HIMS) is gearing up to launch an off-patent version of Novo Nordisk's (NVO) (OTCPK:NONOF) older GLP-1 weight loss therapy liraglutide in 2025, CEO of the telehealth platform ...

The results come as those drugs, like Wegovy and Ozempic, explode in popularity, leading to shortages as well as greater competition. Executives on Monday said those supply constraints were "not ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Police seized more than $35 million in counterfeit Viagra from two Summerville brothers as part of an alleged conspiracy to ...

Let’s cut to the chase: erectile dysfunction (ED) is a common issue, but it’s not the end of the world. We’ve got the inside ...

Investors with a lot of money to spend have taken a bullish stance on Hims & Hers Health (NYSE:HIMS). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Analyst Allen Lutz from Bank of America Securities reiterated a Buy rating on Hims & Hers Health (HIMS – Research Report) and increased the price target to $25.00 from $23.00. Allen Lutz has ...

Any Australian who has filled a prescription at the chemist will have been asked if they want a branded product or the generic version. And with consumers looking to cut costs wherever they can ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

When Adobe Premiere Pro shows the error “The importer reported a generic error” it usually happens when trying to import media files. This error often means ...

Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. The company benefits from GLP-1 drug sales and is ...

In a court decision filed this week in Washington, D.C., U.S. District Judge Dabney Friedrich rejected Novartis’ position that the FDA’s July approval of MSN’s Entresto generic was unlawful.